Please use this identifier to cite or link to this item:
https://ir.swu.ac.th/jspui/handle/123456789/13991
Title: | Impact of age on survival predictability of bone turnover markers in hemodialysis patients |
Authors: | Lertdumrongluk P. Lau W.L. Park J. Rhee C.M. Kovesdy C.P. Kalantar-Zadeh K. |
Keywords: | albumin alkaline phosphatase creatinine parathyroid hormone adult age distribution aged albumin blood level alkaline phosphatase blood level article body mass bone turnover cardiovascular mortality cohort analysis creatinine blood level disease association female groups by age hemodialysis patient human major clinical study male parathyroid hormone blood level priority journal retrospective study age alkaline phosphatase bone turnover markers hemodialysis parathyroid hormone Adolescent Adult Age Factors Aged Aged, 80 and over Alkaline Phosphatase Biological Markers Bone and Bones Bone Remodeling Female Follow-Up Studies Glomerular Filtration Rate Humans Kidney Diseases Kidney Function Tests Male Middle Aged Parathyroid Hormone Prognosis Renal Dialysis Survival Rate Young Adult |
Issue Date: | 2013 |
Abstract: | BackgroundAbnormalities in serum alkaline phosphatase (ALP) and intact parathyroid hormone (PTH) concentrations, as biochemical markers of bone turnover in dialysis patients, correlate with increased mortality in maintenance hemodialysis (MHD) patients. Changes in bone turnover rate vary with age. The mortality predictability of serum ALP and PTH levels in MHD patients may be different across ages.MethodsWe examined differences across four age groups (18 to <45, 45 to <65, 65 to <75 and ≥75 years) in the mortality predictability of serum ALP and PTH in 102 149 MHD patients using Cox models.ResultsHigher serum ALP levels were associated with higher mortality across all ages; however, the ALP-mortality association was much stronger in young patients (<45 years) compared with older patients. The association between higher serum PTH levels and mortality was stronger in older patients compared with the younger groups. Serum PTH levels were incrementally associated with mortality only in middle-aged and elderly patients (≥45 years). Compared with patients with serum PTH 150 to <300pg/mL, the death risks were higher in patients with serum PTH 300 to <600pg/mL [HRs (95% CI): 1.05 (1.01-1.10), 1.15 (1.10-1.21) and 1.25 (1.19-1.31) for patients 45 to <65, 65 to <75 and ≥75 years, respectively], and ≥600pg/mL [HRs(95% CI): 1.07 (1.01-1.14), 1.31(1.21-1.42) and 1.45(1.33-1.59) for age categories 45 to <65, 65 to <75 and ≥75 years, respectively]. However, no significant association between higher serum PTH levels and mortality was observed in patients <45 years.ConclusionsThere are important differences in mortality-predictability of serum ALP and PTH in older MHD patients compared with their younger counterparts. The effect of age needs to be considered when interpreting the prognostic implications of serum ALP and PTH levels. © 2013 The Author. All rights reserved. |
URI: | https://ir.swu.ac.th/jspui/handle/123456789/13991 https://www.scopus.com/inward/record.uri?eid=2-s2.0-84884958861&doi=10.1093%2fndt%2fgft290&partnerID=40&md5=d17304c71b36e57391f89d332857f9b8 |
ISSN: | 9310509 |
Appears in Collections: | Scopus 1983-2021 |
Files in This Item:
There are no files associated with this item.
Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.